BNT327/ PM8002, an investigational bispecific antibody combining PD-L1 checkpoint inhibition with VEGF-A neutralization being developed in collaboration with Biotheus: For more information, please ...
BioNTech has agreed to acquire mRNA specialist CureVac for approximately $1.25bn, as the big pharma company amps up its strategy to offer cancer treatments using the modality. According to the deal, ...
After the University of Pennsylvania and the U.S. National Institutes of Health (NIH) separately pressed BioNTech for royalties on its Pfizer-partnered COVID-19 vaccine Comirnaty, the German drugmaker ...
Covid-19 vaccine makers Moderna and BioNTech became household names almost overnight. Moderna and BioNTech have spent their Covid vaccine windfalls differently, with Moderna investing in its own mRNA ...
BioNTech reported Q1 revenue of $192.23 million, surpassing the consensus of $177.40 million. Cash and investments totaled 15.85 billion euros as of March 31, 2025. Geopolitical tensions, Fed ...
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on discovering and developing antibodies for oncological or inflammatory diseases.
We recently published 11 Best Cancer Stocks to Buy Right Now. BioNTech SE is one of them. BioNTech SE (NASDAQ:BNTX), a German biotechnology company, specializes in mRNA-based immunotherapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results